Can Synthetic Vaccines Change The World’s Approach To Infectious Disease Crises?
Executive Summary
Emerging Company Profile: Emergex Vaccines will use its nanobody technology to develop entirely synthetic immunizations against the world’s most concerning infectious diseases, including Ebola; evolving current options for vaccine stockpiling and national repositories.
You may also be interested in...
HVIVO Seeks Big Pharma Partner For ‘Phase III-Ready’ Universal Flu Vaccine
Presenting Phase IIb data on FLU-v, specialized CRO hVIVO now hopes to secure a big pharma partner for Phase III studies and commercialization of the universal flu vaccine candidate. The product has been developed in a joint venture with SEEK.
Snapshot: July Highlights
A selection of articles you might have missed from July 2020, including exclusive interviews with industry leaders and a review of Q2 financing statistics.
Execs On The Move, July 2020
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Need a specific report? 1000+ reports available
Buy Reports